AC Immune Aktie
| 2,68USD | 0,00USD | 0,00% |
WKN DE: A2AR5F / ISIN: CH0329023102
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 62,11 |
| BVF Partners LP | 19,59 |
| BVF, Inc. | 19,59 |
| dievini Hopp BioTech holding GmbH & Co. KG | 16,37 |
| Rudolf Maag | 12,04 |
| MIG Verwaltungs AG | 6,45 |
| Eli Lilly & Co. | 3,63 |
| Andrea Pfeifer, PhD | 2,43 |
| BlackRock Advisors LLC | 1,95 |
| Redmile Group LLC | 1,70 |
| Wells Fargo Clearing Services LLC | 1,11 |
| BlackRock Health Sciences Opportunities Portfolio | 1,09 |
| Artal Group SA | 1,00 |
| Artal International Management SA | 1,00 |
| Platinum Investment Management Ltd. | 0,96 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 132 | 149 | 143 | 156 | 161 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,85 | 0,11 | 0,00 | 0,03 | 0,10 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 302 | 262 | 222 | 138 | 149 |
| Summe Anlagevermögen | 7 | 8 | 65 | 63 | 69 |
| Summe Aktiva | 309 | 270 | 287 | 201 | 217 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 28 | 26 | 32 | 18 | 26 |
| Summe Eigenkapital | 281 | 244 | 255 | 183 | 191 |
| Summe Passiva | 309 | 270 | 287 | 201 | 217 |
Adresse
| EPFL Innovation Park, 1015 Lausanne | |
| Telefon | +41 (21) 345-91-21 |
| Internet | http://www.acimmune.com |
Management
|
Alexandre Caratsch
General Counsel |
|
Andrea Pfeifer
Chief Executive Officer & Director |
|
Bojana Portmann
VP-Intellectual Property & Business Development |
|
Carl H. June
Independent Non-Executive Director |
|
Christopher Roberts
Chief Financial Officer & Vice President |
|
Douglas E. Williams
Chairman |
|
Gary Waanders
Head-Investor Relations & Corporate Communications |
|
Howard Donovan
Chief Human Resource Officer |
|
Jean-Fabien Monin
Chief Administrative Officer |
|
Julian Snow
VP-US Finance & Corporate Development |
|
Julien Rongère
VP-Regulatory Affairs & Quality Assurance |
|
Madiha Derouazi
Chief Scientific Officer |
|
Mark Danton
VP-Information Systems & Security |
|
Monica Shaw
Independent Non-Executive Director |
|
Monika Bütler
Vice Chairman |
|
Nuno Mendonça
Chief Medical Officer |
|
Oliver Sol
VP & Head-Clinical Development |
|
Piergiorgio Donati
Chief Technical Operations Officer |
|
Roy Ervin Twyman
Independent Non-Executive Director |
|
Sonia Maria Poli
Executive Manager |
|
Werner Lanthaler
Independent Non-Executive Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
